Search Follow us

 

Pixium’s Prima sub-retinal wireless implant continues to advance through human feasibility trials. The EU study recently reached full enrolment and a US study is slated to start implantations in Q318. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €90.6m, vs €77.4m previously.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs